Australia’s Sigma Healthcare has confirmed that it is in early discussions about a possible purchase of Boots, one of the well-known pharmacy and healthcare retail companies in the United Kingdom. These talks have attracted attention because Boots is a major company in the healthcare and retail industry, with thousands of employees and millions of customers across the UK.

Sigma Healthcare said it regularly explores business opportunities that could support future growth and provide value to shareholders. The company confirmed early talks have taken place but said the discussions are still in the initial stage and there is no guarantee that a final deal will happen.

Boots is one of the largest pharmacy chains in the UK and has been serving customers for many years. The company runs more than 1,800 stores across the country and provides a wide range of products and services, including prescription medicines, health products, beauty items, and pharmacy care.

Boots is currently owned by Sycamore Partners, a private equity firm that took control of Boots after acquiring Walgreens Boots Alliance. Since the change in ownership, the company’s future has remained under discussion. Earlier reports Boots might be sold to the public through a stock market listing called an initial public offering (IPO). But, recent updates show that the company may be sold if a suitable buyer is found.

According to reports, the possible value of a Boots sale could be about $10 billion, making it one of the biggest retail and healthcare deals in recent years. If the deal happens, it would be a major move for Sigma Healthcare and could increase its global presence.

This deal comes after Sigma Healthcare joined forces with Chemist Warehouse, creating one of Australia’s largest pharmacy and healthcare groups. This partnership improved the company’s market strength and gave it the ability to pursue bigger business plans. Experts believe the company may now be building on this progress to expand beyond Australia and enter international markets.

Reports also indicate that Sigma Healthcare could face competition from other potential buyers. The Canadian branch of the Weston family, which is known for investing in retail and pharmacy businesses, is also said to be interested in Boots. If more than one buyer takes part in the bidding, competition could increase and may push the final sale price higher.

Boots has recently shown strong business performance even during tough economic conditions for retailers. High demand for beauty products, healthcare services, and prescription medicines has helped support its growth.

Industry analysts say a purchase of Boots would be a major move for Sigma Healthcare. While the opportunity could offer long-term growth, experts mention that big deals often need careful planning, proper funding, and approval from regulators before they can be completed.

At this stage, discussions remain ongoing and no final decision has been announced. Any future agreement would probably need further negotiations and approvals before moving forward. The result of these talks could play an important role in shaping the future of both Sigma Healthcare and Boots in the years ahead.